The company's financial foundation is weakening, as evidenced by total assets contracting from $301.6M in 2023Q2 to $126.7M in 2025Q3 while the accumulated deficit reached -$461.3M.
| Total Current Assets | 124.43M | 171.15M | 243.69M | 353.98M | 351.41M | 346.55M | 98.57M | 12.05M |
| Cash & Short-Term Investments | 112.6M | 152.79M | 223.63M | 343.94M | 341.87M | 333.71M | 94.8M | 10.73M |
| Cash Only | 72.83M | 84.72M | 111.27M | 159.52M | 334.43M | 326.18M | 94.8M | 10.73M |
| Short-Term Investments | 39.78M | 68.07M | 112.36M | 184.42M | 7.44M | 7.53M | 0 | 0 |
| Accounts Receivable | 6.49M | 12.35M | 15.31M | 4.32M | 3.23M | 6.16M | 3.06M | 1.06M |
| Days Sales Outstanding | 346.1 | 84.27 | 109.3 | 11.97 | 155.32 | 16.67K | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 5.33M | 0 | 0 | 0 | 0 | 0 | 719K | 0 |
| Total Non-Current Assets | 2.32M | 5.36M | 10.21M | 10.1M | 17.3M | 10.53M | 4.12M | 1.88M |
| Property, Plant & Equipment | 0 | 4.22M | 7.54M | 9.6M | 13.1M | 8.62M | 3.42M | 1.65M |
| Fixed Asset Turnover | 6.42x | 12.68x | 6.78x | 13.73x | 0.58x | 0.02x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 3.31M | 0 | 2.28M | 0 | 0 | 212K | 208K | 198K |
| Other Non-Current Assets | 600K | 1.14M | 396K | 497K | 586K | 288K | 359K | 27K |
| Total Assets | 126.75M | 176.51M | 253.9M | 364.07M | 368.71M | 357.09M | 102.69M | 13.93M |
| Asset Turnover | 0.08x | 0.30x | 0.20x | 0.36x | 0.02x | 0.00x | - | - |
| Asset Growth % | -158.88% | -30.48% | -30.26% | -1.26% | 3.26% | 247.72% | 637.49% | - |
| Total Current Liabilities | 11.62M | 25.29M | 39.08M | 78.62M | 35.09M | 11.01M | 4.25M | 1.91M |
| Accounts Payable | 1.33M | 3.62M | 2.4M | 461K | 2.3M | 2.25M | 2.13M | 1.25M |
| Days Payables Outstanding | 626.12 | 98.85 | 66.17 | 1.44 | 9.56 | 21.19 | 802.02 | 1.12K |
| Short-Term Debt | 342K | 0 | 2.4M | 0 | 1.72M | 697K | 625K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 10.22M | 53.1M | 11.92M | 2.07M | 0 | 0 |
| Other Current Liabilities | 9.94M | 166K | 17.08M | 16.03M | 13.76M | 3.2M | 233K | 249K |
| Current Ratio | 10.71x | 6.77x | 6.24x | 4.50x | 10.01x | 31.46x | 23.22x | 6.32x |
| Quick Ratio | 10.71x | 6.77x | 6.24x | 4.50x | 10.01x | 31.46x | 23.22x | 6.32x |
| Cash Conversion Cycle | -280.02 | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 88K | 2.74M | 5.94M | 45.2M | 59.24M | 8.58M | 34.4M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.49M |
| Capital Lease Obligations | 88K | 88K | 1.01M | 3.26M | 5.59M | 3.31M | 439K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | -2.68M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 2.68M | 0 | 0 | 0 | 31.91M |
| Total Liabilities | 11.62M | 25.38M | 41.82M | 84.56M | 80.29M | 70.26M | 12.83M | 36.31M |
| Total Debt | 342K | 1.93M | 3.41M | 5.43M | 7.31M | 4M | 1.06M | 2.49M |
| Net Debt | -72.48M | -82.78M | -107.86M | -154.09M | -327.11M | -322.18M | -93.73M | -8.24M |
| Debt / Equity | 0.00x | 0.01x | 0.02x | 0.02x | 0.03x | 0.01x | 0.01x | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 1.00x | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - |
| Total Equity | 115.13M | 151.13M | 212.08M | 279.52M | 288.42M | 286.83M | 89.87M | -22.38M |
| Equity Growth % | -154.8% | -28.74% | -24.13% | -3.09% | 0.55% | 219.17% | 501.48% | - |
| Book Value per Share | 2.67 | 3.56 | 5.04 | 6.67 | 7.63 | 7.77 | 2.45 | -1.42 |
| Total Shareholders' Equity | 115.13M | 151.13M | 212.08M | 279.52M | 288.42M | 286.83M | 89.87M | -22.38M |
| Common Stock | 490.49M | 486.67M | 483.35M | 482.03M | 480.7M | 384.31M | 1K | 1K |
| Retained Earnings | -461.33M | -417.8M | -333.11M | -239.31M | -210.27M | -103.36M | -49.94M | -22.73M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -340K |
| Accumulated OCI | 14K | 54K | 28K | -428K | 0 | 0 | 0 | -490K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Clinical milestone funding dependency
As reported in financial statements, Repare's total assets have declined from $301.6M in 2023Q2 to $126.7M in 2025Q3, a trend that underscores the rapid consumption of capital to fund clinical development in the absence of consistent, recurring revenue streams from its proprietary SNIPRx platform.
The consistent reduction in the asset base suggests that the company is effectively liquidating its balance sheet to finance ongoing R&D activities. Investors should monitor whether this trajectory forces a pivot toward more conservative pipeline management or necessitates further dilutive capital raises to maintain operational continuity.
Based on reported figures, the company's cash position has eroded from $115.5M in 2023Q2 to $72.8M as of 2025Q3, which, when viewed against the backdrop of persistent operating losses, suggests a tightening liquidity buffer that may limit the company's strategic flexibility in upcoming clinical phases.
While the current ratio remains elevated at 10.71, this metric is somewhat deceptive as it is driven by the absence of significant current liabilities rather than an abundance of liquid assets. The rapid depletion of cash reserves indicates that the company is approaching a critical juncture where external financing or new partnership milestones will be required to sustain operations.
According to recent SEC filings, the company's equity base has been significantly impacted by an accumulated deficit that reached -$461.3M in 2025Q3, reflecting the heavy reliance on external capital to offset the substantial costs associated with advancing its DNA damage repair clinical pipeline.
The persistent growth of the accumulated deficit highlights the high-risk nature of the business model, where value creation is entirely back-weighted to future clinical success. The erosion of equity suggests that shareholders are bearing the full brunt of the company's R&D-heavy cost structure, with little protection from retained earnings.
As indicated by the balance sheet data, the near-total absence of PPE and goodwill, with PPE net falling to $0 in 2025Q3, suggests that the company's value is almost entirely tied to intangible clinical assets that are highly sensitive to regulatory and partnership-related outcomes.
The lack of tangible assets implies that there is virtually no collateral value to support debt financing, leaving the company entirely dependent on equity markets. This structural reality makes the balance sheet particularly vulnerable to any negative clinical data readouts or the loss of key strategic partners.
Quick answers to the most common questions about buying RPTX stock.
As of 2024, Repare Therapeutics Inc. (RPTX) had total assets of $176.5M including $171.1M in current assets.
Repare Therapeutics Inc. (RPTX) carries total debt of $1.9M, offset by $152.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Repare Therapeutics Inc. (RPTX) has total shareholders' equity (book value) of $151.1M ($3.56 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Repare Therapeutics Inc. (RPTX) reported a current ratio of 6.77x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.